Graybug Vision, Inc. Sustainability Profile
Graybug Vision, Inc., a pioneering name in the ophthalmic industry, is headquartered in the United States. Founded in 2016, the company focuses on developing innovative therapies for retinal diseases, aiming to transform the treatment landscape for patients suffering from conditions such as age-related macular degeneration and diabetic retinopathy. With a commitment to advancing ocular drug delivery systems, Graybug Vision has made significant strides with its proprietary technologies, including sustained-release formulations that enhance patient compliance and treatment efficacy. The company has garnered attention for its unique approach to drug delivery, positioning itself as a leader in the field. As it continues to expand its operational reach, Graybug Vision remains dedicated to improving vision health and achieving notable milestones in the biopharmaceutical sector.
DitchCarbon Score
How does Graybug Vision, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Graybug Vision, Inc.'s score of 33 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Graybug Vision, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. It is important to note that emissions data may be cascaded from related entities. In this case, Graybug Vision, Inc. has a corporate relationship with CalciMedica, Inc., from which performance data may be derived. However, specific emissions figures or reduction initiatives from CalciMedica, Inc. have not been disclosed. As the industry increasingly prioritises sustainability, Graybug Vision, Inc. may need to consider developing and communicating its climate commitments to align with best practices and stakeholder expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,140 | 0,000 | 0,000 | 0,000,000 |
| Scope 2 | 65,610 | 00,000 | 00,000 | 000,000 |
| Scope 3 | 106,660 | 000,000 | 00,000 | 0,000,000,000 |
How Carbon Intensive is Graybug Vision, Inc.'s Industry?
How Carbon Intensive is Graybug Vision, Inc.'s Location?
Graybug Vision, Inc.'s Scope 3 Categories Breakdown
Graybug Vision, Inc.'s Scope 3 emissions, which increased significantly last year and increased significantly since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with detailed category breakdown helping identify key emission sources across their value chain.
Top Scope 3 Categories
Graybug Vision, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Graybug Vision, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
